Ceribell

Executive Summary

Ceribell is a pioneering medical device company headquartered in Sunnyvale, California, that has developed the first point-of-care electroencephalography (EEG) system designed for rapid triage and continuous monitoring of hospital patients at risk for seizures. Founded in 2015, the company addresses a critical gap in neurology care: traditional EEG systems are bulky, require specialized technicians, and have long setup times, leading to underdiagnosis of nonconvulsive seizures in emergency and ICU settings. Ceribell’s solution combines a headband with dry electrodes and a portable amplifier that can be applied in minutes by any clinician, providing real-time results with cloud-based interpretation support. This innovation significantly reduces time-to-diagnosis and enables broader access to EEG monitoring, potentially improving outcomes for hundreds of thousands of patients annually. The company has garnered strong clinical validation and adoption across leading hospital systems, positioning itself as a leader in the growing digital neurology market. Ceribell is privately held and has not disclosed recent funding rounds, but its technology is commercially available in the United States, with plans for international expansion and new indications. Ceribell’s competitive advantage lies in its ease-of-use, speed, and scalability compared to conventional EEG. The company’s platform has been shown to reduce EEG setup time from hours to minutes, enabling earlier seizure detection and treatment. Additionally, its cloud-based architecture allows for remote interpretation and AI-powered analytics, addressing the shortage of neurologists in many hospitals. With the global epilepsy monitoring market projected to exceed $1.5 billion by 2030, Ceribell is well-positioned to capture share through both capital equipment sales and disposable consumables. However, as a private company, financial transparency is limited, and competition from other simplified EEG systems (e.g., from Natus, Masimo) remains a risk. Overall, Ceribell represents a compelling investment opportunity in the digital health space, with strong clinical evidence and a clear unmet need.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Pediatric EEG Monitoring Indication70% success
• Q2 2026Strategic Partnership or Acquisition by a Major Hospital System or Diagnostic Company60% success
• H1 2026Series C Funding Round to Support Commercial Expansion80% success